Literature DB >> 10974323

Effects of sigma receptor agonists on the impairment of spontaneous alternation behavior and decrease of cyclic GMP level induced by nitric oxide synthase inhibitors in mice.

T Mamiya1, Y Noda, A Noda, M Hiramatsu, K Karasawa, T Kameyama, S Furukawa, K Yamada, T Nabeshima.   

Abstract

In this study, we investigated the involvement of the interaction between sigma receptors and the nitric oxide/cyclic GMP pathway in short term memory in mice, assessed through spontaneous alternation behavior in a Y-maze. N(G)-Nitro-L-arginine methyl ester and 7-nitro indazole, both nitric oxide synthase inhibitors, impaired the spontaneous alternation behavior. These impairments were attenuated by (+) SKF 10,047 and (+) pentazocine, sigma(1) receptor agonists. Further, the sigma(1) receptor antagonist, NE-100, reversed the improvements made by sigma receptor agonists. Cyclic GMP levels and nitric oxide synthase activity in the hippocampus were reduced by treatment with N(G)-nitro-L-arginine methyl ester. The suppressive effects of N(G)-nitro-L-arginine methyl ester on the cyclic GMP levels were reversed by co-treatment with (+) SKF 10,047, but the decline in nitric oxide synthase activity was not. These results suggest that the nitric oxide/cyclic GMP pathway in the hippocampus is responsible for spontaneous alternation behavior in a Y-maze. Further, the ameliorating effects of (+) SKF 10,047 on the impairment of spontaneous alternation behavior may be mediated through activation of guanylate cyclase, but not nitric oxide synthase in the hippocampus of mice.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10974323     DOI: 10.1016/s0028-3908(00)00078-2

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  3 in total

1.  [Gly(14)]-Humanin improved the learning and memory impairment induced by scopolamine in vivo.

Authors:  T Mamiya; M Ukai
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

Review 2.  The pharmacology of sigma-1 receptors.

Authors:  Tangui Maurice; Tsung-Ping Su
Journal:  Pharmacol Ther       Date:  2009-07-18       Impact factor: 12.310

Review 3.  Revisiting the sigma-1 receptor as a biological target to treat affective and cognitive disorders.

Authors:  Kinga Sałaciak; Karolina Pytka
Journal:  Neurosci Biobehav Rev       Date:  2021-11-01       Impact factor: 8.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.